Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Transoral Stapling Benefits the Morbidly Obese

By HospiMedica staff writers
Posted on 13 Nov 2006
A new stapling device that is guided into the stomach endoscopically may help morbidly obese patients for whom non-surgical attempts at weight loss, such as diet and exercise, have failed.

Researchers from Washington University (St. More...
Louis, MO, USA) conducted a pilot study of 12 patients with a history of morbid obesity for at least two and one-half years who underwent transoral gastroplasty (TOGa). All participants were eligible for bariatric surgery according to the U.S. National Institutes of Health (NIH) guidelines, i.e., a body mass index (BMI) higher than 40 or higher than 35 for patients with one or more co-morbidities. Of the 12 participants, 10 were female. The average age was 43, and the average BMI was 44.

After undergoing the procedure under general anesthesia, patients were put on a liquid diet and asked to begin an exercise program. No serious adverse events were reported during or after the procedure. However, minor adverse events included vomiting, posterior pharyngeal pain, temporomandibular joint dysfunction, and post prandial fullness. Each of these was experienced by one participant, and all the events were transient. All patients had significant weight loss at one month of follow-up, with an average weight loss of about 8 kg. The results were reported at the American College of Gastroenterology meeting, held in October 2006 in Las Vegas (NV, USA).

The TOGa transoral stapling device was developed by Satiety Incorporated (Redwood City, CA, USA). The device grabs opposite sides of the stomach lining, holds them together, and inserts a line of staples to partition and shrink the active portion of the stomach down to the size of a golf ball. The procedure takes 30 minutes, and the company claims it will reduce costs of bariatric surgery by 75%.

"Carefully designed long-term randomized controlled studies will be required to demonstrate the efficacy of this device for the treatment of morbid obesity,” said lead author Steven Edmundowciz, M.D. "Although the technique is certainly less invasive than other forms of bariatric surgery, it is not clear that it would be less expensive. We hope that it will be, but we have no idea where the prices will go.”



Related Links:
Washington University

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.